JP2024507131A5 - - Google Patents
Info
- Publication number
- JP2024507131A5 JP2024507131A5 JP2023548258A JP2023548258A JP2024507131A5 JP 2024507131 A5 JP2024507131 A5 JP 2024507131A5 JP 2023548258 A JP2023548258 A JP 2023548258A JP 2023548258 A JP2023548258 A JP 2023548258A JP 2024507131 A5 JP2024507131 A5 JP 2024507131A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- nitrogen
- sulfur
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149095P | 2021-02-12 | 2021-02-12 | |
| US63/149,095 | 2021-02-12 | ||
| US202163166638P | 2021-03-26 | 2021-03-26 | |
| US63/166,638 | 2021-03-26 | ||
| US202163192627P | 2021-05-25 | 2021-05-25 | |
| US63/192,627 | 2021-05-25 | ||
| US202163250473P | 2021-09-30 | 2021-09-30 | |
| US63/250,473 | 2021-09-30 | ||
| US202163292337P | 2021-12-21 | 2021-12-21 | |
| US63/292,337 | 2021-12-21 | ||
| PCT/US2022/016114 WO2022174031A1 (en) | 2021-02-12 | 2022-02-11 | Cdk inhibitors and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507131A JP2024507131A (ja) | 2024-02-16 |
| JP2024507131A5 true JP2024507131A5 (https=) | 2025-02-21 |
Family
ID=82837943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548258A Withdrawn JP2024507131A (ja) | 2021-02-12 | 2022-02-11 | Ｃｄｋ阻害薬及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240190855A1 (https=) |
| EP (1) | EP4291176A4 (https=) |
| JP (1) | JP2024507131A (https=) |
| KR (1) | KR20230173083A (https=) |
| AU (1) | AU2022219987A1 (https=) |
| BR (1) | BR112023015527A2 (https=) |
| CA (1) | CA3210224A1 (https=) |
| CL (1) | CL2023002276A1 (https=) |
| IL (1) | IL305087A (https=) |
| MX (1) | MX2023009086A (https=) |
| PE (1) | PE20231938A1 (https=) |
| TW (1) | TW202246255A (https=) |
| WO (1) | WO2022174031A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023007133A (es) | 2020-12-17 | 2023-06-27 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de estos. |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US11932648B2 (en) | 2021-06-28 | 2024-03-19 | Blueprint Medicines Corporation | CDK2 inhibitors |
| WO2023274397A1 (zh) * | 2021-07-01 | 2023-01-05 | 上海拓界生物医药科技有限公司 | Cdk2抑制剂及其制备方法和用途 |
| AR127247A1 (es) * | 2021-10-05 | 2024-01-03 | Genentech Inc | Inhibidores de cdk2 de ciclopentilpirazol |
| CN116023367A (zh) * | 2021-10-25 | 2023-04-28 | 优领医药科技(香港)有限公司 | 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| WO2023083201A1 (zh) * | 2021-11-09 | 2023-05-19 | 上海拓界生物医药科技有限公司 | 一种氨基吡唑衍生物及其制备方法和用途 |
| IL312642A (en) | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| WO2023111996A1 (en) | 2021-12-17 | 2023-06-22 | Reglagene Holding, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| US20250195475A1 (en) * | 2022-01-27 | 2025-06-19 | InventisBio Co., Ltd. | Cdk2 inhibitor and preparation method and use thereof |
| WO2023154426A1 (en) * | 2022-02-11 | 2023-08-17 | Relay Therapeutics, Inc. | Cdk inhibitors and methods of use thereof |
| WO2023160572A1 (zh) * | 2022-02-24 | 2023-08-31 | 楚浦创制（武汉）医药科技有限公司 | 吡唑类衍生物、药物组合物及应用 |
| CN119072471A (zh) * | 2022-04-28 | 2024-12-03 | 正大天晴药业集团股份有限公司 | 一种吡唑取代环戊酯衍生物及其用途 |
| CN120842212A (zh) * | 2022-06-16 | 2025-10-28 | 昂胜医药有限公司 | 苯胺基-吡唑衍生物、其组合物和方法 |
| US20260041669A1 (en) * | 2022-08-11 | 2026-02-12 | Relay Therapeutics, Inc. | Solid forms of a cdk inhibitor |
| WO2024046443A1 (en) * | 2022-09-01 | 2024-03-07 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocyclic compounds as selective cdk inhibitors |
| CN119998291A (zh) * | 2022-09-09 | 2025-05-13 | 楚浦创制（武汉）医药科技有限公司 | 吡唑类衍生物、药物组合物及应用 |
| IL319513A (en) | 2022-09-13 | 2025-05-01 | Genesis Therapeutics Inc | Compounds for cancer treatment |
| TW202412776A (zh) * | 2022-09-15 | 2024-04-01 | 英屬開曼群島商百濟神州有限公司 | 作為ｃｄｋ抑制劑之雙環化合物 |
| CN119790039A (zh) * | 2022-09-30 | 2025-04-08 | 楚浦创制（武汉）医药科技有限公司 | 氘代吡唑类衍生物、药物组合物及应用与制备方法 |
| CN120239698A (zh) * | 2022-11-17 | 2025-07-01 | 山东绿叶制药有限公司 | Cdk2抑制剂及其制备方法和应用 |
| WO2024123801A1 (en) * | 2022-12-06 | 2024-06-13 | Genesis Therapeutics, Inc. | Compounds for treating cancer |
| WO2024137979A2 (en) * | 2022-12-23 | 2024-06-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Foxm1 inhibitors and their use in treating cancers |
| EP4653431A4 (en) * | 2023-01-19 | 2026-04-29 | Starg Wuhan Pharmaceutical Tech Co Ltd | PYRAZOLE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT, STEREOISOMER, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE |
| WO2024152995A1 (zh) * | 2023-01-20 | 2024-07-25 | 上海海量医药科技有限公司 | 一种大环类细胞周期蛋白抑制剂及其制备方法和应用 |
| US12215102B2 (en) | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
| CN118619950A (zh) * | 2023-03-10 | 2024-09-10 | 浙江同源康医药股份有限公司 | 一类三环类化合物及其制备和应用 |
| KR20260010389A (ko) * | 2023-04-14 | 2026-01-20 | 블루프린트 메디신즈 코포레이션 | Cdk2 억제제 |
| WO2024238570A1 (en) * | 2023-05-15 | 2024-11-21 | Aleksia Therapeutics, Inc. | Cdk2 inhibitor pyrazolopyrimidine compounds |
| WO2025062334A1 (en) * | 2023-09-20 | 2025-03-27 | Beigene Switzerland Gmbh | 4-((5-(3-(4-(pyridin-2-yl)cyclopentyl)-1 h-pyrazol-3-yl)amino)-benzenesulfonamide derivatives and similar compounds as cdk inhibitors for the treatment of cancer |
| CN117510431A (zh) * | 2023-11-08 | 2024-02-06 | 浙江雅辰药物科技股份有限公司 | 一种异噻唑-3-酮及其衍生物、合成方法 |
| WO2025126109A1 (en) * | 2023-12-15 | 2025-06-19 | Ensem Therapeutics, Inc. | Anilino-pyrazole derivatives, compositions and methods thereof |
| WO2025136671A1 (en) * | 2023-12-20 | 2025-06-26 | Ensem Therapeutics, Inc. | Anilino-pyrazole derivatives, compositions and methods thereof |
| WO2025235331A1 (en) * | 2024-05-07 | 2025-11-13 | Nikang Therapeutics, Inc. | Bifunctional compounds containing pyrazolopyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| US7671072B2 (en) * | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
| TWI426074B (zh) * | 2008-04-30 | 2014-02-11 | Nerviano Medical Sciences Srl | ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法 |
| IL284589B2 (en) * | 2019-01-31 | 2025-10-01 | Pfizer | 3–Carbonylamino–5–cyclopentyl–h1–pyrazole compounds with cdk2 inhibitory activity |
-
2022
- 2022-02-11 WO PCT/US2022/016114 patent/WO2022174031A1/en not_active Ceased
- 2022-02-11 CA CA3210224A patent/CA3210224A1/en active Pending
- 2022-02-11 AU AU2022219987A patent/AU2022219987A1/en not_active Abandoned
- 2022-02-11 BR BR112023015527A patent/BR112023015527A2/pt unknown
- 2022-02-11 IL IL305087A patent/IL305087A/en unknown
- 2022-02-11 MX MX2023009086A patent/MX2023009086A/es unknown
- 2022-02-11 PE PE2023002343A patent/PE20231938A1/es unknown
- 2022-02-11 KR KR1020237030200A patent/KR20230173083A/ko not_active Withdrawn
- 2022-02-11 TW TW111105034A patent/TW202246255A/zh unknown
- 2022-02-11 JP JP2023548258A patent/JP2024507131A/ja not_active Withdrawn
- 2022-02-11 US US18/276,946 patent/US20240190855A1/en active Pending
- 2022-02-11 EP EP22753406.2A patent/EP4291176A4/en active Pending
-
2023
- 2023-08-02 CL CL2023002276A patent/CL2023002276A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507131A5 (https=) | ||
| IL301106B1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| WO2024222864A1 (en) | Macrocyclic compounds and therapeutic uses thereof | |
| JP2021532109A5 (https=) | ||
| ES2620316T3 (es) | Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer | |
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| JP5701372B2 (ja) | キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用 | |
| JP2022547952A5 (https=) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2020532529A5 (https=) | ||
| CN101528731B (zh) | 具有 AuroraA选择性抑制作用的氨基吡啶衍生物 | |
| JP2011527994A5 (https=) | ||
| CA2959688C (en) | Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin | |
| JP2020532539A5 (https=) | ||
| IL312845B1 (en) | Extacan derivatives, charge-linkers, and their conjugates | |
| JP2022544714A5 (https=) | ||
| JP2021531311A5 (https=) | ||
| CA2859779A1 (en) | Substituted benzylpyrazoles | |
| MX2013013462A (es) | Compuestos novedosos. | |
| JP2016523973A5 (https=) | ||
| PT1797038E (pt) | Forma termodinamicamente estável de tosilato de bay 43-9006 | |
| KR20160115991A (ko) | Midh1 억제제로서의 벤즈이미다졸-2-아민 | |
| CN114853754B (zh) | 一种硫代酰胺衍生物及其制备方法和应用 | |
| EP2231282A1 (en) | Protein kinase inhibitors and use thereof | |
| JP2009505980A5 (https=) |